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ABSTRACT
Vascular endothelial growth factor (VEGF)-A is differentially spliced to give two functionally different
isoform families; pro-angiogenic, pro-permeability VEGF-Axxx and anti-angiogenic, anti-permeability
VEGF-Axxxb. VEGF-A splicing is dysregulated in several pathologies, including cancer, diabetes, and
peripheral arterial disease. The bichromatic VEGF-A splicing-sensitive fluorescent reporter harboured in
a transgenic mouse is a novel approach to investigate the splicing patterns of VEGF-A in vivo. We
generated a transgenic mouse harbouring a splicing-sensitive fluorescent reporter designed to mimic
VEGF-A terminal exon splicing (VEGF8ab) by insertion into the ROSA26 genomic locus. dsRED expression
denotes proximal splice site selection (VEGF-Axxx) and eGFP expression denotes distal splice site selec-
tion (VEGF-Axxxb). We investigated the tissue-specific expression patterns in the eye, skeletal muscle,
cardiac muscle, kidney, and pancreas, and determined whether the splicing pattern could be manipu-
lated in the same manner as endogenous VEGF-A by treatment with the SRPK1 inhibitor SPHINX 31. We
confirmed expression of both dsRED and eGFP in the eye, skeletal muscle, cardiac muscle, kidney, and
pancreas, with the highest expression of both fluorescent proteins observed in the exocrine pancreas.
The ratio of dsRED and eGFP matched that of endogenous VEGF-Axxx and VEGF-Axxxb. Treatment of the
VEGF8ab mice with SPHINX 31 increased the mRNA and protein eGFP/dsRED ratio in the exocrine
pancreas, mimicking endogenous VEGF-A splicing. The VEGF-A exon 8 splicing-sensitive fluorescent
reporter mouse is a novel tool to assess splicing regulation in the individual cell-types and tissues,
which provides a useful screening process for potentially therapeutic splicing regulatory compounds
in vivo
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Introduction
The alternative splicing of pre-mRNA is the key driver of pro-
teome diversity as it increases the coding capacity of a single gene
[1]. Alternative splicing events are heavily regulated at different
developmental stages, in different tissues and cell-types, under
different conditions. A well-studied example of this regulated
splicing is that of exon 8 of the vascular endothelial growth factor
A (VEGF-A) gene. Within exon 8, use of a proximal 3’ splice site
(PSS) gives rise to the canonical pro-angiogenic family of
VEGF-Axxx isoforms (VEGF-A165, VEGF-A121, VEGF-A181,
etc., with the number denoting the number of amino acids). In
2002, Bates et al. [2] characterized a novel distal 3’ splice site
(DSS) in exon 8, which resulted in a new family of anti-
angiogenic isoforms, termed VEGF-Axxxb, the most dominant
being VEGF-A165b. The VEGF-Axxxb family differ in the
C-terminus by six amino acids, which results in the
VEGF-Axxxb isoforms not being able to phosphorylate VEGF
receptor 2 (VEGFR2) [3,4].
The role of VEGF-A exon 8 splicing in the pathogenesis of
multiple disease-types has been studied, such as cancer, macu-
lar degeneration, nephropathy, preeclampsia, and ischaemic
limb disease [2,5–8]. In many of these diseases, the pro-
angiogenic VEGF-Axxx isoform has been shown to be detri-
mental and therapeutic studies have focused on shifting the
splicing ratio to increase VEGF-Axxxb/VEGF-Axxx [5,6,9]. On
the other hand, increased VEGF-A165b was reported to be
detrimental in a mouse model of ischaemic limb disease [10].
The use of bichromatic splicing-sensitive fluorescent repor-
ters is a novel method used to visualize splicing outcomes in
living cells. It relies on the splice-site regulated expression of
two fluorescent proteins from a single reporter. Such
a method was first reported as a high-throughput cell-based
screen of alternative splicing, which also enables quantitative
single-cell analysis of alternative splicing [11]. This technique,
although with monochromatic reporters, has also been used
in vivo to assess FGFR2 exon IIIc splicing as an indicator of
mesenchymal epithelial transitions in prostate tumours [12].
Furthermore, Bonano et al. reported the insertion of the
FGFR2 exon IIIb silencing reporter into the ROSA26 genomic
locus of mice [13], and thus the ability to follow FGFR2
alternative splicing in the whole organism. A bichromatic
reporter designed on the backbone of the one used by
Orengo et al. [11] to follow FGFR2 exon IIIc splicing was
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also used to image the behaviour of cancer cells in xenografts
and lung metastasis [14]. In addition, a bichromatic trans-
genic mouse model has also been generated to study the
exclusion/inclusion of exon 22 in the Apt2a1 gene [15].
In the present study, we generated a VEGF-A exon 8
splicing-sensitive fluorescent reporter mouse (VEGF8ab)
where dsRED expression denotes PSS selection (pro-
angiogenic, pro-permeability VEGF-Axxx) and eGFP expres-
sion denotes DSS selection (anti-angiogenic, anti-permeability
VEGF-Axxxb). We aimed to determine the reporter expression
and splicing pattern in different tissues of the mouse and
sought to validate whether the reporter expression mimicked
endogenous VEGF-A splicing patterns by treating the mice
with SPHINX 31, a potent and specific inhibitor of SRPK1
reported to increase VEGF-Axxxb relative to VEGF-Axxx [16].
Results
Construction of the reporter mouse
The VEGF-A exon 8 reporter was constructed in-house to
mimic the alternative splicing events in exon 8 (Figure 1(a))
using the backbone of a previous bichromatic reporter
designed for FGFR2 splicing [14]. It contains a CMV promo-
ter, followed by an artificial exon, which includes 11 bases of
exon 7 of VEGF-A and a FLAG-tag. Next is intron 7 and exon
8 of the VEGF-A gene. The VEGF8ab reporter contains
dsRED upstream of eGFP resulting in dsRED and eGFP
being expressed from two different reading frames. Use of
the exon 8 PSS results in the transcription of dsRED followed
by a stop codon. Use of the exon 8 DSS, however, puts dsRED
in the +1 reading frame; eGFP is now in-frame and is tran-
scribed as a fusion protein (Figure 1(b)).
The VEGF-A exon 8 reporter mouse was generated by
GenOway Ltd (France). Vectors harbouring the reporter
were inserted into the ROSA26 genomic locus by homologous
recombination in embryonic stem cells (Figure 1(c)).
Chimeras were screened for germline transmission by PCR
and fluorescence imaging. DNA validation of insertion into
the ROSA26 locus is provided in Fig.S1. Homozygous mice
(VEGF8ab+/+) on a mixed background were used for screen-
ing and experimental studies as they displayed better reporter
expression.
Imaging the expression of the VEGF-A exon 8 splicing
reporter in multiple mouse tissues confirms it
recapitulates the endogenous splicing patterns
PFA-fixed sections from the eye, heart, skeletal muscle, kid-
ney, liver, spleen, lung, and pancreas, as well as retinal and
choroid flat mounts of the eye, underwent microscopic ana-
lysis of reporter splice isoform expression. While there was
very low levels of detection of either isoform in the liver,
spleen, and lung, fluorescence was seen in the eye, kidney,
pancreas and cardiac and skeletal muscle.
Cross-section imaging of the eye from VEGF8ab+/+ mice
showed dsRED expression predominantly in the outer nuclear
layer and the retinal pigmented epithelium (RPE). eGFP was
found to be expressed predominantly in the RPE (Figure 2(a)),
which correlates with endogenous patterns of expression as
VEGF-A165b was previously reported to be expressed in RPE
cells [17]. The localization of the expression of the reporter was
determined by H&E staining and imaging of the same section.
Retinal flat mounts showed both dsRED and eGFP to be
expressed in the retina with some co-localization (Figure 2(b)).
However, only dsREDwas detected in the choroid of VEGF8ab+/+
mice (Figure 2(c)). This indicates that VEGF-A165b is predomi-
nantly expressed in the retina. Furthermore, when looking at the
mRNA expression of both the reporter and endogenous VEGF-A
in the eye, both dsRED and VEGF-Axxxa isoforms were expressed
at a higher level than eGFP and VEGF-Axxxb (Figure 2(d,e)),
indicating that the reportermimics endogenous VEGF-A splicing.
To investigate expression in cardiac and skeletal muscle,
tissue sections from the left ventricle and hind limb skeletal
muscle of WT and VEGF8ab+/+ mice were imaged. Both
dsRED and eGFP expression were detected within cardiac mus-
cle fibres. (Figure 3(a)). Both dsRED and eGFP were also
expressed in the skeletal muscle of VEGF8ab+/+ mice, with
H&E staining confirming that both isoforms were expressed in
both the muscle fibres and blood vessels (Figure 3(b)). These
findings confirm that both splice isoforms of VEGF-A are gen-
erated within the cardiac and skeletal muscle [10].
VEGF-A165b was originally cloned from the human renal
cortex, where it is predominantly expressed in the glomeruli
[2]. When imaging the fluorescent reporter in the kidney, the
reporter was found to be predominantly expressed in the
glomeruli. Individual glomeruli varied in their expression
with some expressing both dsRED and eGFP, whereas others
only expressed dsRED (Figure 4(a); glomeruli circled in yel-
low), suggesting that individual glomeruli express different
ratios of VEGF-A splice isoforms. This confirms previous
observations we made that the variability of individual glo-
meruli permeability may be due to different ratios of the
VEGF-A isoforms [6,18]. Furthermore, RT-PCR analysis of
both the reporter and endogenous VEGF-A splice isoforms in
the renal cortex revealed dsRED and VEGF-Axxxa to be most
highly expressed, whereas no eGFP was detected and lower
levels of VEGF-Axxxb (Figure 4(b,c)). This indicates that the
reporter splicing pattern mimics that of endogenous VEGF-A
in the renal cortex, although not exactly in this case as no
eGFP could be detected with RT-PCR.
Reporter expression and patterns in the pancreas
In the pancreas, both dsRED and eGFP were detected
(Figure 5(a)). Staining for insulin, a marker for pancreatic
β cells, indicated that the reporter was expressed predomi-
nantly in the acinar cells of the exocrine pancreas; these cells
can use the PSS (red arrow), DSS (green arrow), or both
(yellow), and the epithelial cells of the ducts are able to
express both isoforms.
SRPK1 inhibition increased the eGFP/dsRED ratio as well
as endogenous VEGF-A165b expression in the exocrine
pancreas
To determine whether the splicing reporter responds to
administration of small molecules splicing modulators
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in vivo, we administered SPHINX31 (an SRPK1 inhibitor
shown previously to switch splicing towards increasing
VEGF-A165b [16]) intraperitoneally in mice.
Fluorescent imaging of the exocrine pancreas of SPHINX
31-treated VEGF8ab+/+ mice showed a significant increase in
the eGFP/dsRED ratio compared to DMSO-treated controls
(Figure 5(b); p < 0.05). This was due to a change in splicing of
the reporter: a decrease in dsRED and increase in eGFP. The
reporter splicing was also assessed via Western blot analysis of
the reporter Flag-tag expression in the pancreas. Both iso-
forms can be detected using this method as the dsRED
equates to ~35 kDa and the eGFP fusion protein to
Figure 1. VEGF-A exon 8 splicing reporter expression in transgenic mice. (a) Alternative splicing of exon 8 of the endogenous VEGF-A pre-mRNA results in a pro-
angiogenic and anti-angiogenic family of isoforms. (b) Schematic of the VEGF-A exon 8 splicing reporter construct with a CMV promoter. Use of the proximal splice
site (PSS) results in the expression of dsRED; use of the distal splice site (DSS) puts dsRED in the +1-reading frame and eGFP in frame, resulting in the expression of
eGFP fusion protein. A FLAG-tag is located before exon 7. (c) Targeting reporter constructs into the ROSA26 genomic locus. Vectors harbouring the reporter were
inserted into the ROSA26 genomic locus by homologous recombination.
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~65 kDa. The Flag-tag expression of each isoform also showed
a significant increase in the eGFP/dsRED ratio in the pancreas
of SPHINX 31-treated VEGF8ab+/+ mice compared to con-
trols (Figure 5(c); p < 0.05). This switch in splicing was also
confirmed at the mRNA level, with SPHINX 31-treated
VEGF8ab+/+ mice showing an increased eGFP/dsRED ratio
with RT-PCR (Figure 5(e)).
To determine whether the effect of SPHINX 31 on the
VEGF8ab reporter splicing was mimicking the endogenous spli-
cing of VEGF-A exon 8, we measured the VEGF-A165
b/VEGF-A164 isoform expression ratio in the same protein from
each mouse. The VEGF A20 antibody detects all VEGF-A iso-
forms, whereas the VEGF-A165b antibody is specific to the differ-
ent c-terminus of VEGF-A165b. In agreement with the reporter
Figure 2. VEGF-A exon 8 splicing reporter expression in the eye. (a) Cross-section imaging of the eye from WT and VEGF8ab+/+ mice showed dsRED expression
predominantly in the inner nuclear layer and the retinal pigmented epithelium (RPE). eGFP was found to be expressed only in the RPE (scale bar: 100 μm).
haematoxylin and eosin (H&E) staining confirmed the localization of reporter expression. (b) Retinal flat mounts showed dsRED and eGFP expression in the retina
(scale bar: 50 μm). (c) Choroid flat mounts showed only dsRED expression in the choroid (scale bar: 25 μm) (n = 10 mice). (d) RT-PCR for the VEGF-A reporter
indicated higher expression of dsRED (201 bp) than eGFP (135 bp) in the eye, which mimicked the splicing pattern of the endogenous VEGF-A mRNA, where there
was higher expression of VEGF-Axxxa (195 bp) than VEGF-Axxxb (129 bp), as shown in (e) (each lane equates to one mouse).
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splicing pattern, SPHINX 31 increased VEGF-A165b mRNA
(Figure 5(d); p < 0.05) expression relative to VEGF-A164 when
compared to DMSO-treated control mice.
Discussion
We successfully generated a VEGF-A exon 8 splicing-sensitive
fluorescent reporter mouse where dsRED expression denotes
PSS selection (pro-angiogenic VEGF-Axxx) and eGFP expression
denotes DSS selection (anti-angiogenic VEGF-Axxxb). We con-
firmed expression and splicing of the reporter in five tissues; eye,
heart, skeletal muscle, kidney, and pancreas. The highest expres-
sion was observed in the pancreas and dsRED was the predomi-
nant protein expressed in each tissue assessed, as determined by
the dsRED/eGFP ratio in each tissue, as well as by assessing the
mRNA expression by RT-PCR. In addition, the splicing pattern
of the reporter appeared to mimic that of the endogenous gene
in the eye and kidney. Finally, we validated the efficacy of the
VEGF8ab reporter in vivo with SPHINX 31, a potent SRPK1
inhibitor, which increased the eGFP/dsRED ratio in the pan-
creas. This change in the expression ratio of the two fluorescent
proteins shows an increase in the use of the DSS and/or decrease
in the use of the PSS, i.e. an increase in VEGF-Axxxb relative to
VEGF-Axxx.
We chose to assess the VEGF8ab reporter expression in the
eye, muscle, and kidney as these tissues have previously been
widely reported to express the anti-angiogenic VEGF-A165
b. In addition, we found that these tissues successfully
expressed the reporter. Furthermore, we chose to assess the
pancreas as this is where the reporter expression was the
highest.
In the eye, we observed a high expression of dsRED (denot-
ing the pro-angiogenic VEGF-Axxx) in the inner nuclear layer,
photoreceptors, and the retinal pigmented epithelium, as well
as in the vascular choroid. The expression of the pro-
angiogenic VEGF-A is well-documented to be expressed by
most ocular cell types, so this was not surprising. However,
we only observed a detectable level of eGFP expression in the
Figure 3. VEGF-A exon 8 splicing reporter expression in cardiac and skeletal muscle. (a) Fluorescence imaging of tissue sections from the left ventricle of WT
and VEGF8ab+/+ mice indicated both dsRED and eGFP expression within the muscle fibres. The sections were also stained with haematoxylin and eosin (H&E) and to
detect histological structures. (c) Fluorescence imaging of tissue sections from the skeletal muscle of WT and VEGF8ab+/+ mice indicated both dsRED and eGFP
expression within the muscle fibres. H&E staining was then performed to detect histological structures (scale bar: 50 μm) (n = 10 mice).
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retinal pigmented epithelium. This result is in line with
a previous study that confirmed the expression of VEGF-A165
b in a retinal pigmented epithelial cell line [17], and in the
developing retina [19]. The anti-angiogenic VEGF-A165b has
been shown to be therapeutic in animal models of retinal
pathologies, including diabetic retinopathy [20] and oxygen-
induced retinopathy [21], as well as in experimental choroidal
neovascularization [22]. The mRNA expression of both the
reporter and endogenous VEGF-A in the eye revealed that
both dsRED and VEGF-Axxxa were expressed at a higher level
than eGFP and VEGF-Axxxb, indicating that the reporter
mimics endogenous VEGF-A splicing.
The alternative splicing of exon 8 of VEGF-A has been
reported in human and experimental peripheral arterial dis-
ease (PAD) where muscle ischaemia induces an angiogenic
response that is frequently inadequate to meet the tissue
perfusion needs [8]. This study showed that VEGF-A165
b was elevated in muscle biopsies of human PAD, which
inhibited angiogenesis and perfusion recovery in PAD muscle.
Therefore, the observation of both dsRED and eGFP in the
skeletal muscle of these mice is further evidence for the
existence of VEGF-A exon 8 splicing in this tissue. The
VEGF8ab reporter mouse would be a useful tool to assess
VEGF-A exon 8 splicing in a mouse model of PAD, as
described previously [10].
Although there are no reports of VEGF-A exon 8 splice
isoform expression in the cardiac muscle, the circulating
VEGF-Axxx/VEGF-Axxxb isoform balance has been well docu-
mented in both coronary artery disease (CAD) and acute
myocardial infarction (AMI) [23,24]. In both instances, an
increase in circulating VEGF-A165b levels was found to be
associated with a worsened clinical outcome. The VEGF8ab
reporter mouse indicates that the VEGF-A pre-mRNA may be
alternatively spliced in the myocardium as both eGFP and
dsRED expression was observed. Thus, this model has the
potential to assess VEGF-A exon 8 splicing in the myocar-
dium of experimental models of cardiac disease.
The role of VEGF-A165b in the kidney has been well-
documented in recent years. Podocytes, glomerular visceral
epithelial cells, have been reported to express high levels of
both VEGF-A165 and VEGF-A165b [25]. This high expression
of VEGF-A165b is suggested to be the reason for the lack of
angiogenesis in the mature renal cortex as it has anti-
angiogenic but cytoprotective properties [25]. Indeed, several
mouse models of glomerular disease have been shown to have
an increased expression of, or are exacerbated by the
Figure 4. VEGF-A exon 8 splicing reporter expression in the kidney. (a) Fluorescence imaging of kidney sections from WT and VEGF8ab+/+ mice revealed reporter
expression was localized to the glomeruli (circled in yellow). Some glomeruli only expressed dsRED (middle panel), whereas others expressed both dsRED and eGFP
(lower panel; scale bar: 50 μm) (n = 10 mice). (b) RT-PCR for the VEGF-A reporter indicated higher expression of dsRED (201 bp) then eGFP (135 bp) in the renal
cortex, which mimicked the splicing pattern of the endogenous VEGF-A mRNA, where there was higher expression of VEGF-Axxxa (195 bp) than VEGF-Axxxb (129 bp),
as shown in (c) (each lane equates to one mouse).
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overexpression of, VEGF-A164; however, treatment with, or
glomerular over-expression of, VEGF-A165b has been consis-
tently shown to be reno-protective [6,18,26,27]. In the
VEGF8ab reporter mouse, we also observed the expression
of both eGFP and dsRED within the glomeruli, apparently
expressed by the podocytes. Interestingly, we saw examples of
glomeruli with mostly dsRED expression, as well as glomeruli
that expressed both eGFP and dsRED from the same kidney.
Figure 5. VEGF-A exon 8 splicing reporter expression in the pancreas. a. Fluorescence imaging of pancreatic section from WT and VEGF8ab+/+ mice showed high
levels of dsRED and eGFP expression. The β cells within the pancreatic islets were stained with insulin, which showed that the VEGF8ab reporter was predominantly
expressed in the acinar cells of the pancreas, and not the islets (scale bar: 50 μm) (n = 10 mice). Red arrow – predominantly PSS staining, green arrow predominantly
DSS expression, yellow arrow = expression of both. Grey arrow, interstitial Cajal-like cell expressing GFP. Box, = high power image of pancreas. b. VEGF-A exon 8
splicing reporter mice were treated with either DMSO or SPHINX 31 (0.8 mg/kg) three times weekly for 3 weeks (intraperitoneal injection). SPHINX 31 significantly
increased the eGFP/dsRED ratio in the pancreatic acinar cells, as quantified by fluorescence intensity (n = 3 mice, five fields of view from three areas of the pancreas
in each mouse; *p < 0.05, Mann-Whitney test). c. Western blotting for the reporter FLAG-tag also showed a significant increase in the eGFP/dsRED ratio in the
pancreas of SPHINX 31-treated mice, as normalized to the DMSO control mice (n = 3 mice; each lane equates to one mouse; *p < 0.05, Mann-Whitney test).
d. Western blotting for endogenous VEGF-A splicing showed an increase in VEGF-A165b relative to VEGF-A164 in the pancreas of SPHINX 31-treated mice in
comparison to DMSO controls (n = 3 mice; each lane equates to one mouse; *p < 0.05, Mann-Whitney test). e. RT-PCR indicated a shift in the splicing of the reporter
to increase distal splice site (DSS) selection in SPHINX 31-treated mice in comparison to controls (note that these were different mice to those shown in C and D; each
lane equates to one mouse).
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When assessing the glomerular permeability of individual
glomeruli from the same kidney in previous reports, we
observed a range of permeabilities that was suggested to be
due to differing splicing patterns of VEGF-A, the dominant
permeability factor in the kidney [6,18]. The splicing pattern
of the reporter in the glomeruli of VEGF8ab mice in the
present study provides further evidence for this suggestion,
which should be explored further. RT-PCR analysis of both
the reporter and endogenous VEGF-A splice isoforms in the
renal cortex revealed dsRED and VEGF-Axxxa to be most
highly expressed over eGFP and VEGF-Axxxb. This indicates
that the reporter splicing mimics that of endogenous VEGF-A
in the renal cortex, although we were not able to detect any
eGFP mRNA in the renal cortex, which indicates that the
reporter does not fully match the expression levels of the
endogenous isoforms.
Within the pancreas of the VEGF8ab reporter mice, we saw
very high expression of both dsRED and eGFP in the exocrine
pancreas in comparison to the endocrine pancreas. This is evi-
dent in Figure 5 where co-staining with the pancreatic islet
marker insulin revealed the reporter to be predominantly
expressed in the acinar cells, and some cells showing much
stronger GFP than dsRED staining. These cells look similar to
the interstitial Cajal-like cells, previously described in the exo-
crine pancreas [28]. This was unexpected as much of the litera-
ture has focused on the role of VEGF-A in the development of
pancreatic islets [29,30]. Furthermore, to the best of our knowl-
edge, there have been no reports on the alternative splicing of
VEGF-A in the pancreas. The reason why we see such high
expression of the reporter in the exocrine pancreas is likely to
be due to the use of the CMV promoter to drive the reporter,
which has been previously reported to drive gene expression
predominantly in the exocrine pancreas of mice [31]. This
observation prompted us to use this tissue to assess the effects
of SPHINX 31, a SRPK1 inhibitor known to increase the
VEGF-Axxxb/VEGF-Axxx splicing ratio [16]. Indeed, we found
that SPHINX 31 increased the eGFP/dsRED ratio in the exocrine
pancreas at both the mRNA and protein level, which reflected
the increased endogenous VEGF-A165b/VEGF-A164 splicing
ratio. Although the reporter was not a direct representation of
the endogenous splicing pattern in every mouse, which may be
due to the reporter having high expression in cell types that do
not have a high expression level of endogenous VEGF-A, the
same splicing switch was observed overall. In addition, valida-
tion via RT-PCR with primers specific for the VEGF-A splicing
reporter isoforms confirmed that the switch in splicing was not
due to programmed translational read-through to generate
a protein known as VEGF-Axe [32]. Therefore, we can confirm
that the VEGF8ab reporter mouse can be used to screen for
compounds that affect VEGF-A exon 8 splicing in vivo. This
novel tool allows for splicing regulation to be visualized in the
individual cells types and tissues of a living organism.
While during the development of the reporter we ascer-
tained that it spliced correctly by sequencing the RT-PCR
products, we cannot completely exclude the possibility that
a frameshift to a cryptic splice site or an error in translation
may happen in a certain cell type or tissue and therefore give
an artificial fluorescence read-out. However, in the tissues
studied, we see a strong correlation of the behaviour of the
reporter with the behaviour of the endogenous gene, which
would be highly unlikely in the case of an artefact. Also, while
being considered a strong promoter, it seems CMV does not
drive expression of our reporter in some tissues. Variability of
CMV expression in different cell types has been described
before [33]. Ideally, several transgenic lines with different
promoters could be developed, but this is at the moment cost-
prohibitive.
In conclusion, we developed a VEGF-A exon 8 splicing-
sensitive fluorescent reporter mouse (VEGF8ab) and exam-
ined the expression of dsRED and eGFP in the eye, skeletal
muscle, cardiac muscle, kidney, and pancreas. We found that
the reporter splicing pattern mimics that of endogenous
VEGF-A exon 8 splicing when using SPHINX 31 to manip-
ulate VEGF-A splicing in the pancreas. This model could be
useful in the assessment of potentially therapeutic splicing
regulatory compounds in vivo.
Materials and methods
Generation of the reporter construct
The VEGF-A splicing reporter was based on the pRG6 bichro-
matic splicing reporter, which contains restriction sites that
allow for the insertion of the relevant sequences of the VEGF-
A gene; a 2,699bp fragment containing the last 11 bases of
exon 7, intron 7, and exon 8 of the VEGF-A gene. This DNA
fragment was cloned into the RG6 plasmid backbone between
XbaI and AgeI sites. The expression of the resulting PRG8ab
reporter is under the control of a CMV promoter. Coding
then begins with an artificial exon sequence. The stop codons
of exons 8a and 8b were mutated to enable translation of the
fluorescent proteins downstream. The reporter function relies
on dsRED and EGFP being in mutually exclusive reading
frames; proximal splice site selection results in dsRED being
in-frame during translation, which is followed by a stop
codon. On the other hand, distal splice site selection puts
dsRED out of frame, resulting in dsRED+1 being translated,
which forms a fusion protein with the now in-frame EGFP.
Mice analysis
All experiments and procedures were approved by the UK
Home office in accordance with the Animals (Scientific
Procedures) Act 1986. Mice were maintained at the
Biological Services Unit, University of Exeter, UK.
VEGF8ab+/+ mice and wild-type (WT) littermate controls
were euthanized via cervical dislocation according to the Guide
for the Care and Use of Laboratory Animals. Excised organs
were washed in PBS and fixed overnight in 4% paraformalde-
hyde (PFA) at 4°C. Tissues were then embedded in OCT com-
pound (Fisher Scientific) and frozen in dry ice before storing at
−80°C. Frozen 10 μm-thick sections were cut onto poly-prep
slides (Sigma Aldrich) using a cryostat, which were then air-
dried for 30min in the dark. Sections were fixedwith 4%PFA for
10 min at room temperature, before rinsing three times in PBS
for 5 min. Tissue sections were mounted with gel mount con-
taining DAPI (VECTASHIELD). Images were taken using
a Leica DM4000 B LED fluorescent microscope. In some
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instances, coverslips were removed from imaged slides and
tissues underwent Haematoxylin and eosin (H&E) staining
using standard methods.
Treatment with SPHINX 31
Homozygous reporter mice were administered 0.8 mg/kg
SPHINX 31 (kindly provided by Prof J Morris, UNSW) or
DMSO vehicle via intraperitoneal injection three times weekly
for 3 weeks (n = 3 per group). Mice were euthanized as
described above. Three different parts of the pancreas were
sectioned and imaged as described above. Pancreatic tissue
was also collected for protein and mRNA analysis.
Western blot analysis
Pancreatic tissue was homogenized in RIPA lysis buffer with
protease inhibitors (both Fisher Scientific). Denatured protein
samples were run onmini-PROTEAN® TGX Stain Free™ pre-cast
gels (4–15%, BIORAD), which allow for visualization and accu-
rate analysis of the total protein loaded for each sample using
a Gel-Doc™ EZ (BIO-RAD) imaging system. The use of this
system means a housekeeping protein loading control is not
required as the amount of protein on the membrane for each
sample can be quantified. Once protein had been transferred on
to a PVDF membrane, total protein could be quantified.
Membranes were blocked in 3% BSA in TBS plus 0.3% Tween
before being probed with either anti-FLAG (Fisher Scientific),
anti-mouse-VEGF-A165b (21
st Century Biochemicals), or anti-
VEGF A20 (Santa Cruz), all at 1:1000 dilution in 3% BSA-TBS-
Tween (0.3%), at 4°C overnight. As the anti-VEGF was raised in
rabbit and the anti-mouse-VEGF-A165b was raised in mouse, we
were able to probe for both proteins simultaneously. After wash-
ing membranes in TBS-Tween (0.3%), fluorescent secondary
antibodies (LI-COR) were diluted in 3% BSA-TBS-Tween
(0.3%), 1:10,000. Membranes were washed again and imaged
with the LI-COR Odyssey® CLx. Analysis was performed using
the Image Studio software (LI-COR), and the protein of interest
was then normalized to the total protein loaded for each sample,
as quantified by the Gel-Doc™ EZ imaging system (BIO-RAD).
Immunofluorescence
Fixed pancreatic tissue sections were blocked with 3% bovine
serum albumin (BSA) and 5% normal goat serum in PBS for
1 hr before incubating with the primary antibody (anti-
insulin, 1:100, Cell Signalling) diluted in 3% BSA in PBS at
4°C overnight. After washing in PBS, the appropriate fluor-
escent secondary antibody was used (Alexa Fluor) in 3% BSA
in PBS for 2 hr at room temperature. Sections were then
washed in PBS before mounting with gel mount containing
DAPI (VECTASHIELD). Images were taken using a Leica
DM4000 B LED fluorescent microscope using a 40x objective,
or a Leica DMi8 TCSP8 confocal using a 40x objective.
RT-PCR analysis
Pancreatic tissue was immediately frozen on dry ice before RNA
extraction was performed using the RNeasy Mini Kit (Qiagen).
cDNA was then synthesized using the GoScript™ Reverse
Transcription System (Promega). RT-PCR for the reporter was
performed using primers positioned in the artificial exon and
dsRED; F 5’-CATATGCCAAGTACGCCCCCTATTGACG-3’,
R 5’-CTACAGGAACAGGTGGTGGC-3’. The PCR program
consisted of 95ºC for 120 s, 35 cycles of 95ºC for 30 s, 55ºC for
30 s and 72ºC for 60 s, followed by 72ºC for 10min. A band sized
~201 base pairs denotes PSS selection, and a band sized ~135
base pairs denotes DSS selection. Control plasmids that do not
splice were used as positive controls for RT-PCR. RT-PCR for
the VEGF-A splice variants was performed using primers posi-
tioned in exon 7 and THE 3’ UTR of exon 8b of the endogenous
gene; F 5’-TTGTACAAGATCCGCAGACG-3’, R 5’-ATGGATC
CGTATCAGTCTTTCCTGG-3’. The PCR program consisted of
95ºC for 120 s, 39 cycles of 95ºC for 60 s, 55ºC for 60 s and 72ºC
for 60 s, followed by 72ºC for 10 min. This resulted in a PCR
product for VEGF-Axxxb (129 bp) and VEGF-Axxxa (195 bp). All
samples were run with negative controls (without reverse tran-
scriptase; RT-).
Statistical analysis
The statistical analysis was performed using GraphPad Prism
software. Data was tested for normality and when found to be
non-normally distributed, between-group comparisons were
assessed with a Mann-Whitney test. All results are presented
as the average ± standard error of the mean (SEM). Imaging
and analysis was blinded to the researcher to restrict bias.
P values <0.05 were considered statistically significant.
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